Literature DB >> 10435567

P53 and beta catenin expression in chronic ulcerative colitis--associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study.

S V Walsh1, M Loda, C M Torres, D Antonioli, R D Odze.   

Abstract

In patients with chronic ulcerative colitis (CUC), polypoid dysplastic lesions (PDLs) are morphologically similar to sporadic adenomas (SAs), but may be biologically distinct from them and are managed differently. p53 mutations have been shown to occur at an earlier phase in the progression of CUC-associated neoplasia when compared with sporadic colon carcinogenesis. In contrast, APC gene mutations are common and occur at an earlier stage in the development of SA. beta catenin is a cell membrane protein that accumulates in the nucleus of colon cancer cells in response to APC gene mutations. This study was performed to test the hypothesis that CUC-associated PDLs have a different molecular profile than do CUC-associated SAs and therefore may be distinguished on this basis. Mucosal biopsy specimens of 38 benign polypoid epithelial neoplasms (17 CUC-associated PDLs and 21 CUC-associated SAs) from 33 patients with CUC and 13 SAs from patients without CUC (controls) were immunohistochemically stained for p53 and beta catenin and graded as follows: 0 = no staining, 1+ = <50% of cells positive, and 2+ = > or =50% of cells positive. The results were correlated with the clinical and histologic features and compared between the two CUC-associated polyp subgroups. Overall, six (16%) polyps were p53-positive, of which five were CUC-associated PDLs (one 1+ and four 2+) and one was a CUC-associated SA (1+) (p = 0.05). Strong (2+) p53 positivity was detected, however, in only CUC-associated PDLs (4 of 5; 80%). Nine of 32 polyps evaluated for beta catenin were positive and included 1 (8%) of 12 CUC-associated PDLs and 8 (40%) of 20 CUC-associated SAs (p = 0.06). Two of the nine beta catenin polyps were strongly positive, and both were CUC-associated SAs. Non-CUC-associated (control) SAs were positive for p53 and beta catenin in 2 (15%) of 13 and 6 (46%) of 13 cases, but none in a strong (2+) fashion. No differences were observed in p53 or beta catenin staining, between CUC-associated and non-CUC-associated SAs. Neither p53 nor beta catenin expression correlated with any clinical or pathologic features, including size and degree of dysplasia of the polyps. CUC-associated PDLs and CUC-associated SAs may have a different molecular genotype. In patients with CUC, the combination of strong p53 expression and absent or weak beta catenin expression is evidence in favor of a CUC-associated PDL in diagnostically difficult lesions. Furthermore, CUC-associated and non-CUC-associated SAs have a similar P53 and beta catenin immunophenotype and thus provide evidence that they are pathogenetically related neoplasms regardless of the presence or absence of colitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435567     DOI: 10.1097/00000478-199908000-00015

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

Review 1.  Cancer surveillance in inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  1999-12

2.  Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols.

Authors:  Ute Günther; Dajana Kusch; Frank Heller; Nataly Bürgel; Silke Leonhardt; Severin Daum; Britta Siegmund; Christoph Loddenkemper; Maria Grünbaum; Heinz-Johannes Buhr; Jörg-Dieter Schulzke; Martin Zeitz; Christian Bojarski
Journal:  Int J Colorectal Dis       Date:  2011-01-29       Impact factor: 2.571

Review 3.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

4.  Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators.

Authors:  Athamassios Kotsinas; Konstantinos Evangelou; Panayotis Zacharatos; Christos Kittas; Vassilis G Gorgoulis
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 5.  [Polypoid dysplasia in inflammatory bowel disease: differential diagnosis and further diagnostic and therapeutic approaches].

Authors:  S Warich-Eitel; T Katzenberger; M Eck
Journal:  Pathologe       Date:  2011-07       Impact factor: 1.011

6.  Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view.

Authors:  John B Kisiel; David A Ahlquist
Journal:  Therap Adv Gastroenterol       Date:  2013-09       Impact factor: 4.409

7.  Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment.

Authors:  M Vieth; H Behrens; M Stolte
Journal:  Gut       Date:  2006-01-19       Impact factor: 23.059

Review 8.  Colonic crohn disease.

Authors:  Traci L Hedrick; Charles M Friel
Journal:  Clin Colon Rectal Surg       Date:  2013-06

9.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

10.  Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours.

Authors:  T Yoshida; N Matsumoto; T Mikami; I Okayasu
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.